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Background: Airway inflammation, especially neutrophilic airway inflammation, is a cardinal pathophysiologic
feature in chronic obstructive pulmonary disease (COPD) patients. The ideal biomarkers characterizing the
inflammation might have important potential clinical applications in disease assessment and therapeutic
intervention. Sputum myeloperoxidase (MPO) is recognized as a marker of neutrophil activity. The purpose of this
meta-analysis is to determine whether sputum MPO levels could reflect disease status or be regulated by regular
medications for COPD.
Methods: Studies were identified by searching PubMed, Embase, the Cochrane Database, CINAHL and www.
controlled-trials.com for relevant reports published before September 2012. Observational studies comparing
sputum MPO in COPD patients and healthy subjects or asthmatics, or within the COPD group, and studies
comparing sputum MPO before and after treatment were all included. Data were independently extracted by two
investigators and analyzed using STATA 10.0 software.
Results: A total of 24 studies were included in the meta-analysis. Sputum MPO levels were increased in stable
COPD patients when compared with normal controls, and this increase was especially pronounced during
exacerbations as compared with MPO levels during the stable state. Theophylline treatment was able to reduce
MPO levels in COPD patients, while glucocorticoid treatment failed to achieve the same result.
Conclusion: Sputum MPO might be a promising biomarker for guiding COPD management; however, further
investigations are needed to confirm this.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a con-
dition of chronic airflow limitation that is not completely
reversible and is often progressive [1]. It is one of the
leading causes of morbidity and mortality in the world,
resulting in a growing social and economic burden [1].
Airway inflammation is a cardinal pathophysiologic fea-
ture in patients with COPD [2], and assessment of airway
inflammation may therefore play an important role in the
management of COPD and assessment of the disease sta-
tus and prediction of prognosis. Additionally, oxidative* Correspondence: xyao1998@126.com
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reproduction in any medium, provided the ordamage in the lower respiratory tract accelerates the de-
velopment of COPD, and oxidative stress levels are ele-
vated in COPD patients [3].
Neutrophils are a major cellular component of COPD
inflammation [4]. The number of neutrophils is in-
creased in induced sputum and bronchoalveolar lavage
fluid (BALF) of COPD patients, and correlates with dis-
ease severity [1,5]. Usually, the markers such as myelo-
peroxidase (MPO), interleukin-8 (IL-8), leukotriene B4
(LTB4), and human neutrophil lipocalin (HNL) [6] are
used as the mediators of neutrophil activity. According
to the Food and Drug Administration (FDA), ‘With the
exception of lung function tests, there are no well vali-
dated biomarkers or surrogate endpoints that can be
used to establish efficacy for a drug for COPD [7]. The
marker MPO has been systematically studied in an. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Myeloperoxidase (MPO) is a heme-containing perox-
idase expressed abundantly in neutrophils and to a lesser
extent in monocytes [8]. MPO is one the principal en-
zymes released from secondary granules following neu-
trophil activation [9,10]. Although the generation of
oxidants by MPO is beneficial in terms of the immune
response to invading pathogens, there is considerable
evidence that inappropriate stimulation of oxidant for-
mation can result in host tissue damage. Sputum derived
from the surface of the lower respiratory tract mucus is
a direct sample from the lower airways, and analysis of
sputum composition makes non-invasive measurement
of airway inflammation possible. Therefore, sputum MPO
may be a potential non-invasive biomarker that reflects
the severity or prognosis of COPD.
Conventional pharmacotherapy includes bronchodilator
medications (β2 agonists, anticholinergics, and methylxan-
thines) and inhaled glucocorticosteroids (ICS). These can
improve health status, and reduce symptoms and exacer-
bations [1]. However, previous treatment has not been
shown statistically to decrease mortality [11,12]. Novel
anti-inflammatory therapies are therefore being developed
as potential therapeutic agents, a recent study [13] showed
that an MPO inhibitor is able to stop progression of
COPD in an animal model by inhibiting oxidative damage.
The inhibition of MPO may be a novel and useful thera-
peutic treatment for COPD [13].
This is the first meta-analysis about sputum MPO in
COPD patients. There have been many recent studies
reporting changes in MPO level in COPD patients
[14-19]; some of these studies failed to replicate the earlier
results [15,16]. And there were few studies that contained
large samples. Other studies [20-26] also observed the
changes of MPO level before and after anti-inflammatory
treatment, but results were inconsistent. We therefore
performed the first meta-analysis of published studies
examining sputum MPO in COPD patients to determine:
1) whether the MPO level is increased in COPD patients
compared to healthy subjects or asthmatics; 2) whether
there is a difference in MPO level between patients with
stable disease and during acute exacerbation; and 3)
whether anti-inflammatory treatment could reduce the
MPO level.
Materials and methods
Studies were identified in literature searches of PubMed
(1966 to September 2012), Embase (1980 to September
2012), the Cochrane Database (1972 to September
2012), CINAHL (1981 to September 2012), and www.
controlled-trials.com for relevant reports. We used the
following keywords: (sputum OR mucus OR phlegm) AND
(myeloperoxidase OR MPO) AND (Chronic ObstructivePulmonary Disease OR obstructive OR bronchitis OR
pulmonary emphysema OR bronchial hyper-reactivity
OR COPD OR COLD OR emphysema OR airway ob-
struction OR airway inflammation), without language re-
strictions. Additionally, a manual search was conducted
using all reviews on this topic, which provided bibliog-
raphies of original reports. Inclusion criteria were: 1) ob-
servational studies or randomized controlled trials (RCT);
2) studies comparing MPO level in COPD patients with
healthy subjects or asthmatics or themselves; and 3) par-
ticipants were adults with COPD as diagnosed by GOLD
[1] or the American Thoracic Society or European Re-
spiratory Society (ATS/ERS) standards [27].
Exclusion criteria were: 1) the MPO value in disease
was provided without control values [28-33]; 2) the
study did not produce original data [34-42]; or 3) the
study investigated sputum MPO but not in COPD pa-
tients [43-45].
Two reviewers (AZ and DG) independently scanned
the titles and abstract sections of all the articles retrieved
based on the explicit criteria. Full articles were searched
when the information met the inclusion criteria. Dis-
agreements in extracted data were resolved by discussion
with a third review author (XY).
Quality evaluation was conducted for each randomized
controlled trial (RCT) with the Jadad criteria [46]. The
trials with a score of 3 to 5 were enrolled in our study.
For each accepted study, we extracted the following data,
when available: the number of participants (n), age, gen-
der, clinical features, treatment (s), method of sputum
sampling, method of MPO measurement, MPO value.
The MPO value was presented as mean value or stand-
ard deviation (SD), standard error of the mean (SEM),
95% confidence interval (95% CI), median or interquar-
tile range and the percent predicted values of FEV1 (%
pred FEV1) in each group. The SEM or 95% CI was
transformed into SD, using a statistical formula. If the
study provided medians and interquartile ranges, we im-
puted the means and SDs as described by Hozo et al.
[47]. We calculated the lower and upper ends of the
range by multiplying the difference between the median
and upper and lower ends of the interquartile range by 2
and adding or subtracting the product from the median,
respectively. If the article provided an MPO value in
chart form, we used the Engauge Digitizer 4.1 software
to estimate its value, and then calculated the mean and
SD with SPSS software(Version 16.0, SPSS Corporation,
College Station, Chicago, USA). For articles where data
were not complete, the authors were contacted. Subject
characteristics are given in more detail in Additional
file 1 [see Additional file 1: Table S1-S3]. Analyses were
performed using STATA software (Version 10.0, STATA
Corporation, College Station, TX, USA). The standard
mean difference (SMD) was chosen to combine statistics
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and resulted in large heterogeneity. Summary estimates
and the weightings for each outcome were evaluated
based on the DerSimonian- Laird random effects model.
Heterogeneity of study results was tested using the
Mantel- Haenszel method, and results were considered
heterogeneous if the P value was <0.05. We used the
I2 statistic to measure the level of statistical heterogen-
eity for each outcome [48]. We used a fixed effects
model when I2 was equal or less than 50%, and a ran-
dom effects model when I2 was greater than 50%. Publi-
cation bias was evaluated through visual inspection of
funnel plots, using the Begg’s test [49] and the Egger’s
Asymmetry test [50]. Publication bias was assumed to be
present if the P value was less than 0.05.
Results
In the primary literature search, 405 records were identi-
fied, of which 262 were unique. After screening the titles
and abstracts, 219 studies were excluded because they
were either animal studies, review articles, or irrelevant
to the current analysis, yielding 43 candidate studies. Of
the 43 reports selected for detailed evaluation, 19 studies
were further excluded for various reasons (Figure 1).
Finally, 24 articles were included in our meta-analysis.
Among the 24 studies, three directly provided SD, nine
studies used the SEM. We transformed the SEM from
these nine studies into SD. Four studies used medians
and the other four studies provided interquartile ranges,Figure 1 Results of the systematic literature search.with the one remaining study providing 95% CI. We in-
putted these into SDs. In addition, we used the Engauge
Digitizer 4.1 software to estimate the MPO value, and
then used SPSS software to calculate the mean value of
the MPO level in the other three studies (data are pre-
sented as mean ± SD). All studies provided basic infor-
mation and detailed methodology for patients and
controls. The characteristics of these studies were listed
in Additional file 1. There was no evidence of publica-
tion bias (Begg’s Test: P = 0.221; Egger’s test: P = 0.161).
The Funnel plot is shown in Figure 2.
1. MPO levels in COPD patients and healthy subjects.
Data were extracted from five articles [14-16,51,52] fo-
cusing on MPO levels in COPD patients compared to
healthy subjects. The overall SMD of MPO levels was
1.43 (95% CI 0.10 to 2.76, P = 0.036; I2 = 91.5%; random
effects model). COPD patients showed higher sputum
MPO levels as compared to healthy subjects (Figure 3).
2. MPO levels in COPD patients and asthmatics.
Four articles [14,15,17,51] compared MPO levels in
COPD patients with asthmatics. The SMD of MPO levels
between the two groups was 0.34 (95% CI −0.31 to 0.99,
P = 0.301; I2 = 73.7%; random effects model). There was
no statistically significant difference between COPD pa-
tients and asthmatics (Figure 4).
Figure 2 Publication Bias.
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acute exacerbations.
Six articles [18,19,53-56] focused on the difference in
MPO levels in stable COPD patients and patients with
exacerbations. Five of them compared the MPO levels
within COPD patients before and after exacerbation,
while the remaining study compared MPO levels in
COPD patients with those in healthy controls. There-
fore, the former five articles were chosen for subgroup
analysis. The overall SMD of MPO levels was 1.06 (95%Figure 3 Myeloperoxidase (MPO) levels in chronic obstructive pulmonCI 0.17 to 1.95, P = 0.019; I2 = 90.6%; random effects
model) between the stable COPD group and exacerba-
tion group. COPD patients with exacerbation showed
a significantly higher MPO level than stable COPD
patients (Figure 5).
4. The changes of MPO level before and after
theophylline treatment.
Three RCT articles [20-22] compared changes of MPO
levels before and after theophylline treatment. The SMDary disease (COPD) patients and healthy subjects.
Figure 4 Myeloperoxidase (MPO) levels in chronic obstructive pulmonary disease (COPD) patients and asthmatics.
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effects model), indicating theophylline treatment could re-
duce MPO levels in sputum of COPD patients (Figure 6).
5. The changes of MPO level before and after
glucocorticoid treatment.
Four RCT articles [23-26] studied the effect of steroid
treatment (including inhaled and oral corticosteroids) on
the sputum MPO value. The SMD of MPO in COPD pa-
tients before and after glucocorticoid treatment was 0.05
(95% CI-1.02 to 1.13, P = 0.921; I2 = 88.7%; random effects
model) indicating that glucocorticoids had no effect on
MPO levels in sputum of COPD patients (Figure 7).Figure 5 Myeloperoxidase (MPO) concentrations in stable chronic ob6. The changes of MPO level before and after other
treatments.
Gompertz et al. [57] and Gronke et al. [58] showed a
small decrease in sputum MPO level in the patients
treated with LTB4 receptor antagonists on sputum MPO
levels in COPD patients. And the difference had no stat-
istical significance (P = 0.06). The other three studies
[44,59,60] also showed no difference in patients treated
with macrolide antibiotics and tulobuterol.
7. The changes of MPO levels between COPD patients
with and without homozygous (PiZ) α1-antitrypsin
(AAT) deficiency.structive pulmonary disease and during acute exacerbation.
Figure 6 The changes before and after theophylline treatment.
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COPD patients without homozygous (PiZ) α1-antitrypsin
(AAT) deficiency were compared with COPD patients
with AAT deficiency. The overall SMD was −0.31 (95%
CI-0.64 to 0.03, P = 0.075; I2 = 0%; fixed effects model)
(Figure 8), indicating that there was no significant differ-
ence between the two groups.
Discussion
This meta-analysis demonstrated that sputum MPO levels
were significantly increased in stable COPD patients as
compared with normal controls but not different fromFigure 7 The changes of myeloperoxidase (MPO) before and after gluthose seen in asthmatic subjects (P = 0.301). It also
indicated that MPO levels were also markedly increased
during exacerbations compared to the stable state. Theo-
phylline treatment significantly reduced sputum MPO
levels, while glucocorticoid treatment had no effect. In
addition, the COPD subjects with AAT deficiency appeared
to have higher sputum MPO levels than those with normal
AAT, although this did not reach statistical significance.
The elevation of sputum MPO levels in COPD pa-
tients correlated with the increased number of neutro-
phils in their respiratory tract [62], indicating that
neutrophil activation was associated with degranulationcocorticoid treatment.
Figure 8 The changes of myeloperoxidase (MPO) levels in chronic obstructive pulmonary disease (COPD) patients with and without
homozygous (PiZ) α1-antitrypsin (AAT) deficiency.
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ered to contribute substantially to the microbicidal activ-
ity of neutrophils and monocytes through the generation
of reactive oxidant species [10]. In particular, the com-
bination of MPO, its substrate hydrogen peroxide
(H2O2), and a halide results in a powerful and effective
antimicrobial system [63]. MPO has also been implicated
in the induction of lung injury. For example, while the
infusion of glucose oxidase or peroxidase alone pro-
duced little damage in in vivo studies, the combination
of the two resulted in interstitial fibrosis [64]. MPO re-
lease results in increased amounts of H2O2 induction,
which is compatible with the MPO system playing a
role in epithelial cell injury in man [65]. As such, MPO
has opposing roles as an effective antimicrobial which
can, to some degree, be replaced and as a detrimental
agent that has the potential to produce damage and
contribute to disease [9]. Perhaps, interventions that re-
duce MPO level might be anticipated to modify the
progression of COPD.
It is known that inflammation seen in asthma is differ-
ent from that seen in COPD with inflammation from
asthma being predominantly eosinophilic rather than
neutrophilic bronchitis [66]. As such, the levels of spu-
tum MPO in COPD patients was higher than that in
asthma patients. However, the difference was not signifi-
cant, and the results may suggest that activation of neu-
trophils may also occur in asthmatics [14] or that the
presence of chronic expectoration in COPD patients
may complicate sputum analysis. Of course, more re-
search and further work in this area is needed.Our study has shown that COPD patients with exacer-
bations had elevated sputum MPO levels relative to their
clinically stable state. This is consistent with the fact that
COPD exacerbations, especially in bacterial exacerba-
tions [19], are triggered by neutrophilic inflammation
[40]. Apart from the study of Fens et al. [67], which sug-
gested that there was no significant difference in sputum
MPO level between GOLD stage I and II, few studies
have investigated whether MPO levels are associated
with disease severity. Further studies are required to de-
termine this.
Previous studies showed that theophylline induces
neutrophil apoptosis through adenosine A2A receptor
antagonism [68] and by reduced O2
− production in both
granulocytes and eosinophils [69]. Liboshi et al. [70]
suggested that long-term treatment with theophylline
reduced inflammatory cytokines and neutrophils in the
sputum of COPD patients. Theophylline, therefore, has
an inhibitory action on airway inflammation, particu-
larly in relation to the activation of inflammatory cells
including neutrophils. This may explain why theophyl-
line significantly reduced the sputum levels of MPO in
COPD patients.
Interestingly, glucocorticoid treatment was found to
have no effect on sputum MPO level in COPD patients,
regardless of the route of administration and dosage,
which further demonstrated that airway neutrophilic in-
flammation is not responsive to glucocorticoids [25]. Al-
though clinically, some COPD patients could benefit from
glucocorticoids, it might be due to the inhibition of the
‘eosinophilic component’ of the inflammatory process in
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COPD patients with neutrophil inflammation do not re-
spond well to steroids. This may also explain the discrep-
ancies between different studies regarding glucocorticoid
effects in the treatment of airway anti-inflammation in
COPD patients [71,72]. More recent laboratory studies
suggest that low-dose theophylline may reverse steroid
resistance by enhancing decreased histone deacetylase
(HDAC)-2 activity [73]. However, no study confirmed
whether combined medications could affect the MPO
level in COPD patients. More translational research in this
area is clearly required.
Two studies [57,58] determined the effect of oral leu-
kotriene B4 (LTB4) receptor antagonists on sputum
MPO levels in COPD patients. Gompertz et al. [57]
showed a decrease in sputum MPO level in the patients
treated with BAYx1005, perhaps because LTB4 can in-
duce the migration of neutrophils into the lungs [74]
and play a role in leukocyte degranulation [75]. But this
failed to achieve statistical significance. Furthermore, the
reproducibility of repeated measurements of MPO in the
Gronke et al. [58] study was also less than satisfactory.
These data failed to demonstrate that sputum MPO
levels, and by implication, airway inflammation in COPD
are modulated by LTB4 receptor antagonists.
Two additional studies [59,60] evaluated the anti-
inflammatory effect of macrolide antibiotics on sputum
MPO levels in COPD patients. The course of treatment
varied from 10 days to 12 months. There was no signifi-
cant difference in sputum MPO levels regardless of the
duration of treatment. In addition, Kanehara et al. [22]
also demonstrated no significant effect of tulobuterol on
sputum MPO levels in mild-to-moderate COPD. Over-
all, these data suggest that only theophylline has a con-
sistent effect on sputum MPO levels. Larger studies will
need to be performed to determine whether other anti-
inflammatory agents affect sputum MPO.
COPD subjects with AAT deficiency appear to have
higher sputum MPO levels, probably because these pa-
tients may associate with a general increase in the con-
centrations of several neutrophilic airway inflammatory
parameters. Hubbard et al. suggested that alveolar
macrophage release of LTB4, the major chemoattractant
responsible for the increased neutrophil migration, is
increased in AAT deficiency as a result of free elastase
activity [76]. The latter can reduce the secretion of
secretory leukoprotease inhibitor (SLPI) [77], as well as
the increase in the permeability of airway cells. However,
recent studies have indicated that the relationship be-
tween LTB4 and MPO is less clear [41]. No statistically
significant difference in the sputum MPO level was ob-
served between COPD patients with AAT deficiency and
those with normal AAT levels in our study. However,
more studies are needed to confirm this.Our meta-analysis has some limitations. The most ob-
vious one is that the methods of collecting and treating
sputum varied in different studies, and the few studies
available prevented subgroup analyses. Another major
limitation is the lack of standardization of sputum MPO
measurement. The MPO level or its activity was assessed
by radioimmunoassay (RIA) or enzyme-linked immuno-
sorbent assay (ELISA) or the substrate O-dianisidine
dihydrochloride assay, so the difference in mean values
was large, resulting in a large heterogeneity, and we
failed to perform the metaregression because of few
studies. Ideally, further large-sample studies are needed
to address the role of MPO in COPD patients.Conclusions
Our study showed a higher MPO level in the sputum of
COPD patients compared with control subjects, espe-
cially during exacerbations. Theophylline decreased spu-
tum inflammation, especially neutrophilic inflammation,
which was accompanied by a decrease in sputum MPO
level. Further investigations are needed to determine
whether sputum MPO levels alter according to disease
severity. MPO might be a potentially useful non-invasive
biomarker of estimating airway inflammation in guiding
COPD patients’ treatment. The sputum MPO level will
contribute to assess the occurrence of any exacerbations.
The inhibition of MPO may be a promising therapeutic
treatment for COPD.Additional file
Additional file 1: Table S1. Studies included in the meta-analysis
examining myeloperoxidase (MPO) levels in chronic obstructive pulmonary
disease (COPD) patients and healthy subjects and asthmatics. Data are
expressed as *mean ± SEM; #mean ± SD; &medians; ^ interquartile ranges;
$:95% confidence interval. M, male; F, female; n, the number of participants;
FEV1, forced expiratory volume in one second; ELISA, enzyme-linked
immunosorbent assay; DDT, dithiothreitol. Table S2. Studies included in the
meta-analysis examining myeloperoxidase (MPO) levels in stable COPD and
during acute exacerbations. Data are expressed as *mean ± SEM; #mean ±
SD; &medians; ^ interquartile ranges; $:95% confidence interval. COPD,
chronic obstructive pulmonary disease; M, male; F, female; n, the number
of participants; FEV1, forced expiratory volume in one second; AAT,
α1-antitrypsindeficiency; ELISA, enzyme-linked immunosorbent assay; ICS,
inhaled corticosteroids. Table S3. Studies included in the meta-analysis
examining myeloperoxidase (MPO) levels in COPD patients before and after
medicine treatment. Data are expressed as *mean ± SEM; #mean ± SD;
&medians; ^ interquartile ranges; $:95% confidence interval. COPD, chronic
obstructive pulmonary disease; M, male; F, female; n, the number of
participants; FEV1, forced expiratory volume in one second; ELISA,
enzyme-linked immunosorbent assay.Abbreviations
AAT: α1-antitrypsindeficiency; BALF: bronchoalveolar lavage fluid;
COPD: chronic obstructive pulmonary disease; ELISA: enzyme-linked
immunosorbent assay; ICS: inhaled glucocorticosteroids LTB4, leukotriene B4;
MPO: myeloperoxidase; RCT: randomize controlled trial; RIA: radioimmunoassay;
SD: standard deviation; SEM: standard error of mean; SMD: standard mean
difference; WMD: weighted mean difference; 95% CI: 95% confidence interval.
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